Just noticed something interesting brewing in the surgical robotics space that Wall Street might be sleeping on.

So Intuitive Surgical has been absolutely crushing it with their da Vinci robot system. They've got over 11,100 of these installed globally, and here's the kicker - about 75% of their revenue isn't even from selling the robots themselves. It's the recurring stuff: instruments, accessories, services. That's the real money machine. But the stock's already priced in all this success. Wall Street has bid it up to a P/E of 64, which is pretty lofty for a medical device company.

Meanwhile, there's this other player that just got FDA approval and is quietly entering the US market. Medtronic launched their Hugo surgical robot, with first procedures already happening. And here's what caught my attention - their P/E is sitting at 27. That's still not cheap, but it's less than half of what Intuitive Surgical is trading at.

The play here is interesting because if Hugo gains traction like da Vinci did, Wall Street is probably going to wake up and start repricing Medtronic. That's typically when valuations move.

Now, Medtronic isn't a pure-play robotics story like Intuitive. They've got cardiovascular, neuroscience, and other surgical divisions. That diversification probably caps how much the stock can run if Hugo takes off, but it also means less risk if it doesn't.

One thing I like about Medtronic that Intuitive doesn't offer - they actually pay a dividend. Around 2.9% yield with decades of increases behind it. So you're getting paid to wait while you see how Hugo develops.

The company's been in development mode for years without much exciting to show, so investors are definitely in show-me mode right now. But buying before Wall Street realizes the potential could be the move here. That's usually when the real gains happen - when the institutional money finally catches on.